Dyadic International (DYAI) vs IN8bio (INAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Dyadic International (DYAI) over the past year, losing 42.7% versus a loss of 60.7%. Over five years, DYAI leads with a -90.8% price change compared with -99.2% for INAB. Dyadic International is the larger company by market cap ($17.9 million vs $13.3 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | INAB |
|---|---|---|
| Share price | $0.447 | $1.35 |
| Market cap | $17.91M | $13.26M |
| 1-day change | +0.59% | -2.54% |
| YTD return | -52.72% | -41.03% |
| 1-year return | -60.67% | -42.74% |
| 5-year return | -90.84% | -99.23% |
| EPS (TTM) | $-0.23 | $-1.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $2.73 |
| 52-week low | $0.34 | $0.88 |
| Distance from 52-week high | -72.06% | -50.73% |
| Analyst consensus | none | none |
| Avg. price target upside | +1130.43% | +420.45% |
| Average volume | 201.91K | 58.36K |
| Shares outstanding | 40.06M | 9.86M |
| Employees | 5 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed DYAI by 17.9 percentage points over the past year.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
DYAI vs INAB FAQ
Which is bigger, Dyadic International or IN8bio?
Dyadic International (DYAI) is larger, with a market capitalization of $17.91M compared with $13.26M for IN8bio (INAB).
Which stock has performed better over the past year, DYAI or INAB?
INAB returned -42.74% over the past 12 months, compared with -60.67% for DYAI (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and IN8bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.